Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intrexon Corp (XON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,781,105
  • Shares Outstanding, K 120,290
  • Annual Sales, $ 190,930 K
  • Annual Income, $ -186,610 K
  • 36-Month Beta 1.51
  • Price/Sales 14.61
  • Price/Cash Flow 0.00
  • Price/Book 5.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.43 +3.97%
on 07/18/17
25.30 -7.83%
on 07/05/17
-0.75 (-3.12%)
since 06/27/17
3-Month
18.89 +23.45%
on 05/09/17
26.99 -13.60%
on 05/15/17
+1.85 (+8.62%)
since 04/27/17
52-Week
18.41 +26.67%
on 04/06/17
32.90 -29.12%
on 11/16/16
-2.25 (-8.80%)
since 07/27/16

Most Recent Stories

More News
Pfizer's Mylotarg Recommended by FDA Advisory Committee

Pfizer Inc. (PFE) announced that the FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML)....

XON : 23.58 (+1.99%)
ZIOP : 5.92 (-0.67%)
SGEN : 54.44 (-1.05%)
PFE : 32.85 (-0.12%)
Oxitec Launching Friendly(TM) Aedes Project in Juiz de Fora, Brazil

OXFORD, England, July 11, 2017 /PRNewswire/ --

XON : 23.58 (+1.99%)
Oxitec Launching Friendly(TM) Aedes Project in Juiz de Fora, Brazil

Oxitec Ltd., a wholly-owned subsidiary of Intrexon Corporation (NYSE: XON), today announced Oxitec do Brasil has signed a contract to launch the Friendly(TM) Aedes Project in Juiz de Fora, Brazil. Juiz...

XON : 23.58 (+1.99%)
Oxitec's Friendly(TM) Aedes Mosquito Receives Positive Evaluation for European Standard in relation to Human Health and the Environment

The National Institute of Public Health and the Environment (RIVM) in the Netherlands today published its "Technical evaluation of a potential release of OX513A Aedes aegypti mosquitoes on the island of...

XON : 23.58 (+1.99%)
Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen

Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Helen Sabzevari,...

XON : 23.58 (+1.99%)
ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma

ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the initiation of enrollment in the stereotactic arm of its Phase 1 multicenter study...

XON : 23.58 (+1.99%)
ZIOP : 5.92 (-0.67%)
$2.65 Billion NGS-based RNA-seq Market by Products & Services, Technology, Application, End User - Global Forecast to 2022

Research and Markets has announced the addition of the "NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology, Application (De novo, Transcriptome...

A : 60.09 (+0.62%)
PACB : 3.28 (-1.50%)
ILMN : 177.01 (+0.40%)
XON : 23.58 (+1.99%)
Intrexon acquires GenVec

Bioindustrial company Intrexon Corporation (NYSE:XON) revealed on Friday the completion of the acquisition of GenVec Inc (NASDAQ:GNVC) for an undisclosed value.

GNVC : 7.19 (-0.28%)
XON : 23.58 (+1.99%)
Why Is Intrexon (XON) Down 4.1% Since the Last Earnings Report?

Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

XON : 23.58 (+1.99%)
Intrexon and Johnson Matthey Collaborate on Fermentative Production of Peptide-based Active Pharmaceutical Ingredients

Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and Johnson Matthey (LN: JMAT), a global leader in...

JMPLD : 70.0000 (-1.41%)
XON : 23.58 (+1.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include...

See More

Support & Resistance

2nd Resistance Point 23.67
1st Resistance Point 23.40
Last Price 23.58
1st Support Level 22.90
2nd Support Level 22.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.